<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04477837</url>
  </required_header>
  <id_info>
    <org_study_id>HEMBLED</org_study_id>
    <nct_id>NCT04477837</nct_id>
  </id_info>
  <brief_title>Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants</brief_title>
  <official_title>Prospective, Observational, Non-interventional Open-label Multicenter Registry Regarding the Incidence of Heavy Menstrual Bleeding in Women of Reproductive Age Treated With Direct Oral Anticoagulants Because of Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardioangiologisches Centrum Bethanien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardioangiologisches Centrum Bethanien</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective comparison of the incidence of heavy menstrual bleeding (HMB) in women of
      reproductive age treated with direct oral anticoagulants (DOACs)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be treated as standard of care, no randomization schedule, no blinded
      investigational product (IP).

      The decision which DOAC will be given is made before the subject will enter the trial. The
      DOAC has to be taken at least for seven days.

      The registry is non-interventional (NIS) with routine blood draw at baseline and at month 4
      after inclusion. The prospective follow up will be up to four months. Three consecutive
      menstrual bleeding cycles will be documented by the participating patients at home. One
      baseline data reporting and one follow up reporting after four months are planned in the
      participating coagulation centers.

      The primary aim is the comparison of the frequency of heavy menstrual bleeding in female
      patients of reproductive age anticoagulated with DOACs using a modified pictorial blood loss
      assessment chart.

      Secondary aims are the prevalence of von Willebrand disease in young anticoagulated female
      patients and correlation of HMB with age, International Society of Thrombosis and Hemostasis
      bleeding assessment tool at inclusion, Blood group, anatomical reasons i.e. underlying
      uterine pathologies, i. e. presence of uterine fibroids, endometrial polyps and/or
      adenomyosis, occurrence of iron deficiency, hemoglobin level and intermittent use of
      non-steroidal anti-inflammatory drug (NSAID).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Months</target_duration>
  <primary_outcome>
    <measure>Primary observation point (for all patients)</measure>
    <time_frame>baseline and monthly up to month 4</time_frame>
    <description>Frequency of heavy menstrual bleeding in anticoagulated female patients of reproductive Age using a modified Pictorial blood loss assessment Chart (PBAC)-Score (Higham, Br J Obstet Gynaecol 1990; 97: 734-9)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary observation points (for all patients)</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>Correlation of heavy menstrual bleeding with von Willebrand's disease; Age; ISTH-BAT-Score at inclusion; blood Group; anatomical reasons i.e. underlying uterine pathologies, i.e. presence of uterine fibroids, endometrial polyps and/or adenomyosis; iron deficiency; hemoglobin level; intermittent use of NSAR</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Heavy Menstrual Bleeding</condition>
  <arm_group>
    <arm_group_label>direct oral anticoagulant (DOAC) No.1</arm_group_label>
    <description>Apixaban 5mg, oral, twice daily for at least four months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>direct oral anticoagulant (DOAC) No.2</arm_group_label>
    <description>Rivaroxaban 20mg, oral, once daily for at least four months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>direct oral anticoagulant (DOAC) No.3</arm_group_label>
    <description>Edoxaban 60mg, oral, once daily for at least four months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>direct oral anticoagulant (DOAC) No.4</arm_group_label>
    <description>Dabigatran 150mg, oral, twice daily for at least four months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban 5 MG</intervention_name>
    <description>frequency of heavy menstrual bleeding</description>
    <arm_group_label>direct oral anticoagulant (DOAC) No.1</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 20 MG</intervention_name>
    <description>frequency of heavy menstrual bleeding</description>
    <arm_group_label>direct oral anticoagulant (DOAC) No.2</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban 60 MG</intervention_name>
    <description>frequency of heavy menstrual bleeding</description>
    <arm_group_label>direct oral anticoagulant (DOAC) No.3</arm_group_label>
    <other_name>Lixiana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran 150 Mg Oral Capsule</intervention_name>
    <description>frequency of heavy menstrual bleeding</description>
    <arm_group_label>direct oral anticoagulant (DOAC) No.4</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Expected number of patients estimated by study duration n=250 patients treated with direct
        oral anticoagulants (DOAC) due to venous thromboembolism.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with venous thromboembolism

          -  Age: 18 - 45 years

          -  Regular menstrual bleeding

          -  Treatment with DOACs for at least 7 days before inclusion

          -  Full therapeutic anticoagulation with rivaroxaban 1 x 20 mg, apixaban 2 x 5 mg,
             edoxaban 60mg once daily or dabigatran 2 x 150mg for at least the next four months

          -  Written informed consent

        Exclusion Criteria:

          -  Hysterectomy or ovariectomy

          -  Known heavy menstrual bleeding

          -  Hormonal contraceptives

          -  Hormone replacement therapy

          -  Use of hormone releasing intrauterine System (IUS)

          -  Contraindications to treatment with DOACs

          -  Treatment with rivaroxaban 15 mg twice daily (first three weeks after diagnosis of
             venous thrombosis) or apixaban 10 mg twice daily (first week after diagnosis of venous
             thrombosis)

          -  Treatment with rivaroxaban (10 mg or 15 mg once daily) or apixaban (2,5 mg twice
             daily) in reduced therapeutic dosages

          -  Participation in any other trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edelgard Lindhoff-Last, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardioangiologisches Zentrum Bethanien</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edelgard Lindhoff-Last, Prof.</last_name>
    <phone>+49-699450280</phone>
    <email>e.lindhoff-last@ccb.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardioangiology Center Bethanien (CCB)</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardioangiologisches Centrum Bethanien</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. E. Lindhoff-Last</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

